These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 32100180)
1. Study of the combined effects of PTH treatment and mechanical loading in postmenopausal osteoporosis using a new mechanistic PK-PD model. Lavaill M; Trichilo S; Scheiner S; Forwood MR; Cooper DML; Pivonka P Biomech Model Mechanobiol; 2020 Oct; 19(5):1765-1780. PubMed ID: 32100180 [TBL] [Abstract][Full Text] [Related]
2. Computational model of the dual action of PTH - Application to a rat model of osteoporosis. Trichilo S; Scheiner S; Forwood M; Cooper DML; Pivonka P J Theor Biol; 2019 Jul; 473():67-79. PubMed ID: 31009612 [TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265 [TBL] [Abstract][Full Text] [Related]
4. Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women. Adami S Curr Med Res Opin; 2008 Nov; 24(11):3259-74. PubMed ID: 18940041 [TBL] [Abstract][Full Text] [Related]
5. Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis. Cipriani C; Pepe J; Silva BC; Rubin MR; Cusano NE; McMahon DJ; Nieddu L; Angelozzi M; Biamonte F; Diacinti D; Hans D; Minisola S; Bilezikian JP J Bone Miner Res; 2018 Dec; 33(12):2132-2139. PubMed ID: 30088838 [TBL] [Abstract][Full Text] [Related]
6. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596 [TBL] [Abstract][Full Text] [Related]
7. The cellular and clinical parameters of anabolic therapy for osteoporosis. Rosen CJ Crit Rev Eukaryot Gene Expr; 2003; 13(1):25-38. PubMed ID: 12839095 [TBL] [Abstract][Full Text] [Related]
8. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. Meng XW; Liang XG; Birchman R; Wu DD; Dempster DW; Lindsay R; Shen V J Bone Miner Res; 1996 Apr; 11(4):421-9. PubMed ID: 8992872 [TBL] [Abstract][Full Text] [Related]
9. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84. Recker RR; Bare SP; Smith SY; Varela A; Miller MA; Morris SA; Fox J Bone; 2009 Jan; 44(1):113-9. PubMed ID: 18983947 [TBL] [Abstract][Full Text] [Related]
10. LY353381 x HCl: an improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1-34). Sato M; Zeng GQ; Rowley E; Turner CH Endocrinology; 1998 Nov; 139(11):4642-51. PubMed ID: 9794476 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis. Henriksen K; Andersen JR; Riis BJ; Mehta N; Tavakkol R; Alexandersen P; Byrjalsen I; Valter I; Nedergaard BS; Teglbjaerg CS; Stern W; Sturmer A; Mitta S; Nino AJ; Fitzpatrick LA; Christiansen C; Karsdal MA Bone; 2013 Mar; 53(1):160-6. PubMed ID: 23234813 [TBL] [Abstract][Full Text] [Related]
12. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. Rittmaster RS; Bolognese M; Ettinger MP; Hanley DA; Hodsman AB; Kendler DL; Rosen CJ J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440 [TBL] [Abstract][Full Text] [Related]
13. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Greenspan SL; Bone HG; Ettinger MP; Hanley DA; Lindsay R; Zanchetta JR; Blosch CM; Mathisen AL; Morris SA; Marriott TB; Ann Intern Med; 2007 Mar; 146(5):326-39. PubMed ID: 17339618 [TBL] [Abstract][Full Text] [Related]
14. Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study. Zanchetta JR; Bogado CE; Cisari C; Aslanidis S; Greisen H; Fox J; Lems W Curr Med Res Opin; 2010 Nov; 26(11):2627-33. PubMed ID: 20923256 [TBL] [Abstract][Full Text] [Related]
15. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. Dempster DW; Cosman F; Kurland ES; Zhou H; Nieves J; Woelfert L; Shane E; Plavetić K; Müller R; Bilezikian J; Lindsay R J Bone Miner Res; 2001 Oct; 16(10):1846-53. PubMed ID: 11585349 [TBL] [Abstract][Full Text] [Related]
17. Parathyroid hormone in the treatment of osteoporosis. Fujita T BioDrugs; 2001; 15(11):721-8. PubMed ID: 11707147 [TBL] [Abstract][Full Text] [Related]
18. Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats. Shen V; Birchman R; Xu R; Otter M; Wu D; Lindsay R; Dempster DW J Clin Invest; 1995 Nov; 96(5):2331-8. PubMed ID: 7593620 [TBL] [Abstract][Full Text] [Related]
19. Effects of Intermittent Parathyroid Hormone 1-34 Administration on Circulating Mesenchymal Stem Cells in Postmenopausal Osteoporotic Women. Tang Y; Xia H; Kang L; Sun Q; Su Z; Hao C; Xue Y Med Sci Monit; 2019 Jan; 25():259-268. PubMed ID: 30620727 [TBL] [Abstract][Full Text] [Related]
20. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Compston JE Bone; 2007 Jun; 40(6):1447-52. PubMed ID: 17045858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]